Research on causality of fibroblast growth factor 23 (FGF-23) in a range of cardiovascular diseases has been published in a new article in the Clinical Journal of the American Society of Nephrology. The study tested the hypothesis of association between FGF-23 genetic score and atherosclerotic and non-atherosclerotic cardiovascular outcomes. FGF-23 genetic score was formed through inclusion of 34 independent variants of circulating FGF-23 identified in 19,195 individuals from SCALLOP consortium data and validated in 4,390 genotyped individuals from the ORIGIN trial.
The study demonstrated that genetically-predicted FGF-23 was not associated with risk of atherosclerotic or non-atherosclerotic cardiovascular disease.
- Donovan K., Herrington W., Paré G., Pigeyre M., Haynes R., Sardell R., Butterworth A., Folkersen L., Gustafsson S., Wang Q., Baigent C., Mälarstig A., Holmes M., Staplin N. (2022). Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. Clinical Journal of the American Society of Nephrology, 17(12). Αrticle link